Title:  2011 ICAAC, Renewed Optimism over Antimicrobial Prospects

Publication: Micro Magazine

Date: December 2011

URL: link to website 

Summary

Several newly developed cyclic amidrazone or amidoxime derivatives of oxazolidinone display activity against linezolid-resistant gram- positive pathogens, according to Yong-Zu Kim of LegoChem Biosciences in Daejeon, South Korea. With linezolid still the only oxazolidinone approved for human use, he says, "we are continuing to optimize our lead compound and to support further development for use against gram-positive pathogens."

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).